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Entrepreneurship & Global Health: Catalyzing the Ecosystem  
ABSTRACT  
Innovative financing for global health may stimulate new waves of entrepreneurial activity.  
Global policies have created new sources of financing to accelerate knowledge generation for 
healthcare in resource-poor settings. This article outlines the emerging research concerned 
with the entrepreneurial response to opportunities and incentives at the bottom of the pyramid 
for healthcare.  Questions arise to what kind of business models can be used to provide 
affordable healthcare on a viable basis.  We examine public-private partnerships as one 
mechanism to catalyze the ecosystem and draw in stakeholders to contribute to the innovation 
value chain.  We integrate entrepreneurship, innovation and ecosystem theories to discuss 
how the entrepreneurial firm builds resources and creates value in the healthcare ecosystem. 
Keywords: entrepreneurship, global health, innovation value chain, resource-based theory, 
policy & practice 
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1. Executive Summary 
This article addresses responses from the private sector to inequities in global health.  
New global policies have been designed to create incentives for healthcare innovation by 
mitigating risks for science-based business. These policies have been mainly directed at large 
pharma companies. Whether and how viable entrepreneurial innovation can be stimulated 
depends on business models adopted by entrepreneurs, the topic of inquiry in this paper.  
The global healthcare ecosystem is complex with many interdependent business, 
social and political stakeholders influenced by developments in supply, demand and 
institutional arrangements.  National policy makers not only provide oversight of the 
operations of healthcare firms, but also shape conditions affecting inputs through their 
regulations.  To focus on business management and entrepreneurship, we examine the 
healthcare ecosystem of the entrepreneurial firm, our unit of analysis, to see how such firms 
can drive innovation in the value chain, guiding new concepts through discovery, 
development and diffusion.    
A framework is proposed, combining the resource-based view of entrepreneurship, 
with concepts from innovation and business ecosystem literature.  The case exemplar selected 
centers on the public-private partnership of the Meningitis Vaccine Project (MVP), a program 
established in 2000 solely for the purpose of eliminating meningitis epidemics in sub-Saharan 
Africa.  MVP was founded by a $70M USD, 10-year grant by the Bill and Melinda Gates 
Foundation and has 21 primary stakeholders.  MVP provides an illustration of a public-
private partnership mobilizing resources in both public and private sectors, involving donor 
countries and foundations aiming at a common goal.  Empirical evidence focuses on the 
innovator private sector firm, SERUM Institute of India Ltd (“SERUM”) as an 
entrepreneurial innovator within the MVP partnership. SERUM matched its internal 
capabilities to opportunities in the innovation ecosystem to achieve commercialization for 
MenAfriVacTM, the world’s first vaccine approved for meningitis A.  The MVP public-
private partnership has brought together primary and secondary stakeholders in an innovation 
ecosystem that supports entrepreneurial activity in global health.  Using a resource-based 
framework, we extend entrepreneurship theory beyond conventional applications and point to 
new business models for global health entrepreneurs.  
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2. Introduction 
The global disease burden is not distributed equally1.  Communicable, maternal, 
perinatal and nutrition-related diseases (classified as diseases of poverty) add up to over 50% 
of the disease burden of developing countries – nearly ten times higher than their burden in 
developed countries (Commission on Intellectual Property Rights, 2006).  There is global 
demand for access to more biomedical knowledge, products and services. The costs of 
innovations have limited access for many patients in resource-poor settings (Henry & 
Lexchin, 2002; Pecoul, Chirac, Trouiller, & Pinel, 1999; Trouiller, et al., 2002).  For 
neglected diseases2, global supply is not able to fully meet demand. Studies show that rises in 
biomedical research funding have been aligned with disease burden in high-income countries, 
but not linked to new drug approvals (Dorsey, et al., 2009). Furthermore, of all chemical 
entities marketed between 1975 and 1999, only 1% were for neglected diseases (Trouiller, et 
al., 2002).   
Health inequalities have been correlated with conflict, international security and 
economic development (MacQueen & Santa-Barbara, 2000; Sachs, 2005).  The response by 
global governing bodies has been to provide funding for global health (Group, 2010; Hecht, 
Wilson, & Palriwala, 2009; Moses, Dorsey, Matheson, & Thier, 2005; Ravishankar, et al., 
2009).  Funding grants have also been made conditional on collaborating between 
stakeholders in the global healthcare ecosystem.  This consists of primary stakeholders 
including patients, knowledge generation centres (public academic institutions and private 
life sciences firms), their suppliers, employees, partners and funders.  Secondary stakeholders 
of the ecosystem include the systems of national healthcare within which these players 
operate, local communities, regulators, patient advocacy groups, civil society, non-
governmental organizations and the broader scientific community.  Almost all of the 
stakeholders in the healthcare ecosystem hold inter-locking relationships with each other and 
often cross boundaries between primary and secondary stakeholder status. 
                                                        
1 World Health Report 2008. Primary health care: now more than ever. Geneva, World Health Organization 
2009 (http://www.who.int/whr/2008/whr08_en.pdf) accessed October 18, 2010.  
2 World Health Organization defines Type I diseases: which are incident in both rich and poor countries, with 
large numbers of vulnerable populations in each.  Type II diseases: are incident in both rich and poor countries, 
but with a substantial proportion of the cases in poor countries.  Type III diseases: are defined being those that 
are overwhelmingly or exclusively incident in developing countries.  Type II diseases are often termed 
neglected diseases and Type III diseases are often termed very neglected diseases. (Commission on Intellectual 
Property Rights, 2006) 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Neglect of diseases has resulted from lack of effective demand and purchasing power 
by patients in poor countries. Entrepreneurs, as agents of change, have historically 
demonstrated ability to exploit neglected opportunities associated with human need (Nairn, 
2002).  Enterprise initially propelled adoption of industrial innovations such as the railroads 
and chemical companies in the 19th century and what became large scale science businesses 
such as DuPont AT&T (Bell Laboratories) and General Electric (Chandler, 1977; Pisano, 
2010).  However, in new science-based businesses such as biotechnology and healthcare, the 
convergence of science with business has presented difficulties in long-term risk 
management, knowledge integration and learning (Pisano, 2006).  How science-based 
entrepreneurs discover and develop opportunities that lie beyond the pull of existing markets 
calls for further inquiry (Hall, Daneke, & Lenox, 2010). Here we examine how new financing 
sources can mitigate the risks of science and technology targeted at previously neglected 
diseases.  Decreased risk can encourage new forms of entrepreneurial activity in the global 
health ecosystem. 
To organize thinking on this complex topic we apply a resource-based entrepreneurial 
framework to the global health ecosystem to elucidate new sources of entrepreneurial and 
business model innovation.  The paper is structured as follows: the first section addresses 
knowledge gaps in global healthcare and research on how public-private partnerships can 
provide opportunities for business to generate relevant knowledge.  The second section 
proposes the conceptual framework that guides our research question and shows how this can 
be informed by evidence-based constructs.  The third section utilizes a case study as an 
exemplar, applying the conceptual framework to empirical evidence from the Meningitis 
Vaccine Project.  
The MVP partnership concentrated its development with the entrepreneurial firm 
SERUM Institute of India (“SERUM”).  This paper builds on resource-based theory 
(Penrose, 1995; Wernerfelt, 1984) in relation to the innovation value chain (Afuah, 2003; 
Hansen & Birkinshaw, 2007), informing the framework with evidence on how SERUM 
utilizes a public-private partnership model to create and capture value in the global health 
ecosystem. 
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3. The recognition of existing knowledge gaps in global health  
Developmental economists have shown that the burden of disease directly impacts 
country development (Collier, 2007; Sachs, 2005) and weak health systems help perpetuate 
the poverty cycle (Kremer & Glennerster, 2004).  In developing countries, poverty decreases 
purchasing power and the inability of the poor to pay reduces effective demand, curbing the 
market pull incentive for private enterprise. The supply and demand mechanisms that reward 
private firms are largely absent in resource-poor settings.   
In surveys conducted by the United Nations World Health Organization (WHO) 
developed countries account for 12% of the worldwide burden of disease from all causes of 
death and disability and account for 90% of all health expenditure worldwide (Murray & 
Lopez, 1997).  The tension between the need for innovations to prevent and treat diseases in 
developing countries and the very constrained resources in these countries is widely 
recognized (Hotez, et al., 2007).   
Recognition on this situation has led to greater priority being accorded to healthcare 
issues, leading to a quadrupling of donor assistance funding for health from $5.6 billion in 
1990 to $21.8 billion in 2007 (Ravishankar, et al., 2009).  The increase in funding has given 
rise to new coordination and mobilizing organizations such as The Global Fund to fight 
HIV/AIDS, Tuberculosis and Malaria and the GAVI Alliance for vaccines and 
immunizations.  However even with increased funding, governments alone cannot resource 
and manage the healthcare innovation cycle of discovery, development and delivery.  Private 
sector involvement is needed (Commission on Intellectual Property Rights, 2006). For 
example, two relevant initiatives have been made to engage private sector firms on the 
development agenda of resource-poor countries.  New partnerships are arising from UK’s 
Department for International Development (DFID) through its Private Sector unit3 and US 
Agency for International Development’s (USAID)’s Development Innovation Ventures 
(DIV) to support “game-changing innovations” through a combination of push and pull 
mechanisms4.  A new global trend is emerging, involving partnerships between the private 
business sector and international development agencies. 
                                                        
3 UK DFID Private Sector Unit Lauch October 12, 2010 http://www.dfid.gov.uk/Media-Room/News-
Stories/2010/Mitchell-Private-sector-holds-the-key-to-tackling-global-poverty/ - accessed October 15, 2010  
4 USAID Announces Development Innovation Ventures October 8, 2010 http://www.dfid.gov.uk/Media-
Room/News-Stories/2010/Mitchell-Private-sector-holds-the-key-to-tackling-global-poverty/ - accessed 
February 2, 2011 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3.1 The recognition of opportunities emerging at the bottom of the pyramid for health 
Bottom of the pyramid markets offer significant sources of entrepreneurial 
opportunities (Hart, 2005; Prahalad, 2006) for private sector businesses with a market-
oriented solution.  Business models can be adapted to serve the poor and yet provide 
commercial viability for the enterprise (Prahalad & Hammond, 2002).  Public partners and 
government national health systems could help reduce risk, integrate knowledge and diffuse 
innovations to achieve social impact (Gardner, Acharya, & Yach, 2007; Hecht, et al., 2009).  
For the most part, private entrepreneurial firms have not tackled diseases of the 
developing world because they have assumed only in developed countries is there purchasing 
power for technological innovations.   However, new studies argue that although consumers 
at the bottom of the income pyramid have low individual levels of disposable income, on an 
aggregate basis, consumer demand is extensive (Hammond, Kramer, Katz, Tran, & Walker, 
2007; Karamchandani, Kubzanasky, & Frandano, 2009; Prahalad, 2006). It is estimated that 
populations living in low and middle-income countries comprise a $158 billion market 
opportunity for healthcare products and services (Hammond, et al., 2007).  To access bottom 
of pyramid consumers, entrepreneurial firms, governments and global aid agencies are 
exhorted to consider the principles of affordability, access and availability of innovations 
(Prahalad, 2006).  Applying these three principles to health innovations appears to be 
essential for reducing health inequities.   
To address affordability and access, increased funds have been targeted at healthcare 
logistics and delivery capabilities in resource-poor countries.  Of particular interest here, 
financing incentives have been established to encourage public and private sectors to work 
together to address availability of drugs and services that target the disease burden in 
developing countries and overcome the market supply gap (Taskforce, 2009a, 2009b).   
New funding sources provide two types of support for entrepreneurial firms: push and 
pull incentives.  Push programs are primarily supply-side grants and subsidies that reduce the 
costs of research inputs; they include grants to university academics and tax credits for firms 
engaging in R&D activities.  Pull programs operate from the market demand side of the 
spectrum, increasing the potential rewards for commercialization success and providing a 
higher payment for research outputs (Kremer & Glennerster, 2004).  Examples of pull 
incentives include a purchase guarantee of a product/service at a certain quantity or at a 
certain price.  Both push and pull methods can be used to spur innovations that serve the 
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bottom of the pyramid populations (Group, 2010).  Large multinational firms have begun 
implementing the principles of serving the poor profitably (Immelt, Govindarajan, & 
Trimble, 2009; Webb, Kistruck, Ireland, & Ketchen, 2009), and policy changes to increase 
funding could also be used to attract smaller entrepreneurial firms.  
There has been a shift in public health polices in recognition of the possibility of new 
business models to deliver healthcare knowledge, goods and services.  Push and pull 
incentives are being provided to enable private partners, small and large, to participate in 
both knowledge generation and knowledge delivery of health innovations.  Entrepreneurial 
thinking, both from the public and private sectors can extend the boundaries of internal 
capabilities and add synergies in new resource combinations (Burgelman, 1983). 
 
3.2 The entrepreneurial response to new opportunities through public-private 
partnerships 
As part of the effort to improve healthcare provision, global product development 
partnerships have developed since the mid 1990s (Buse & Walt, 2000).  These partnerships 
mobilize resources in both the public and private sectors and involve donor countries and 
foundations united in pursuit of a common health goal.  Partnerships for international 
development between donors and recipient countries is a concept originating from the 
Pearson Commission of 1969 (Pearson, 1969).  In the healthcare context, the World Health 
Organization describes partnerships with the private sector as a means to “bring together a set 
of factors for the common goal of improving the health of populations based on mutually 
agreed roles and principles” (Buse & Walt, 2000).  The working definition of public-private 
partnerships includes three points: partnerships must involve at least one private for-profit 
organization with at least one not-for-profit organization, core partners provide a joint sharing 
of efforts and of benefits, partnerships in public health are committed to the creation of social 
value (aimed at improving health) especially for disadvantaged populations (Reich, 2000). 
Increasingly, private philanthropic foundations have operated as catalysts in the 
funding of global product development partnerships and health aid, reaching 27% ($5.2 
billion) of health aid in 2007 (Ravishankar, et al., 2009).  Philanthropic foundations and 
public sector aid donors support the project management infrastructure of the partnerships 
and create a platform to engage the private sector.   
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The partnership basis of these global product development partnerships encourages 
interdisciplinary collaboration in the ecosystem.  Push funding derived from partnerships can 
mitigate product development failure risk as well as provide additional technical support to 
the entrepreneurial firm.  This can reduce some of the risks experienced by firms that need to 
engage in scientific R&D as depicted by (Pisano, 2010), and extend the reach of 
entrepreneurial innovation.  
 Public-private health partnerships also provide pull incentives for the private sector.  
Partnership stakeholders can play funding roles, technical roles as well as a procurement role 
for the final product developed. The difficulty in reaching small, segmented markets for 
health can be overcome with a coordinated approach that can be facilitated by a public-
private partnership.  
 
4. Research perspectives from the field of management studies 
The research question examined here is as follows: what business models can enable 
entrepreneurs to provide affordable healthcare innovations on a viable basis? The unit of 
analysis examined is the entrepreneurial firm within its wider ecosystem.  This approach is 
used as a basis for integrating themes from entrepreneurship, policy, and technology 
innovation.    
The importance for firms of selecting an appropriate business model in creating value 
is increasingly recognized (Teece, 2010).  However, prior research concentrates on 
innovation in resource-rich environments.  Less attention has been paid to innovative 
business models in developing country contexts.  We explore this knowledge gap through the 
application of a model of entrepreneurial value generation (Figure 1). This is applied here to 
new and established firms that offer products and services to users at the bottom of the 
income pyramid.  The conceptual model makes it possible to map out the elements of 
entrepreneurial activity and identify how new firms or units of existing firms may adapt their 
business models to fit resource-poor settings.   
Influential definitions of entrepreneurship focus on economic opportunity (Kirzner, 
1979; Schumpeter, 1934) and pursuit (Shane & Venkataraman, 2000).  In contrast, it can be 
argued, following earlier work by Penrose (1995), that the novel ways in which entrepreneurs 
build resources for their ventures is no less critical to their success (Freeman, 1982).  Thus 
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key features of entrepreneurial innovation are to be found not only in the way opportunities 
are identified, created and pursued, but in the novel matching of a firm’s resources to 
opportunity in order to create value in new ways (Garnsey, 1998).   
Evidence from an entrepreneurial firm active in a wider health partnership (MVP) is 
presented as an exemplar.  A single case study can be justified to inform a conceptual 
framework.  It is not claimed that such a case is representative, but rather that it can provide 
theoretical and empirical insight: “it is often desirable to choose a particular organization 
precisely because it is very special in the sense of allowing one to gain certain insights that 
other organizations would not be able to provide” (Siggelkow, 2007, p. 20).  Single case 
studies have provided insight for influential studies in management studies, e.g. (Penrose, 
1960; Schein, 2010). 
The case study method is applied to investigate entrepreneurship and global health in 
this paper. This approach makes it possible to inform a conceptual model with evidence in 
order to illuminate poorly understood phenomena (Eisenhardt, 1989).  Qualitative research 
can provide rich evidence needed for understanding “why” and “how” questions relating to 
entrepreneurial motivation and behavior in firms (Yin, 2003).  Qualitative research of this 
kind draws on the inductive and interpretative tradition (Van Maanen, 1983).  Primary 
evidence from face-to-face interviews are particularly valuable (Walsham, 1995), and were 
undertaken for this inquiry.  In selecting interview subjects, researchers are encouraged to 
find individuals with the requisite experience to offer understanding of the case history 
through their own experience (Greenhalgh & Taylor, 1997; Patton, 1990).  To guard against 
retrospective bias, such testimonies should be checked against secondary evidence obtained 
from archives, company documents and press reports.  Case evidence was gathered through 
primary semi-structured interviews with the chief MVP project director and implementation 
staff of MVP partners.  Triangulation was conducted through secondary and archival data 
research and use of public press releases on the 10-year development timeline of the project.  
 The case selected provides insight into many dimensions of the issues addressed in 
this paper.  SERUM Institute of India Limited (SERUM’s) business model in developing the 
meningitis A vaccine relies on its mutual cooperation with the Meningitis Vaccine Project 
(MVP), a public-private development partnership.  While maintaining its regular operations, 
SERUM has been able to diversify into a new disease area (meningitis) with a new 
vaccination technology.  The case shows how product development partnerships may help 
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firms achieve new business models to generate value for both producers and users.  But to 
accomplish this, they may have to create for themselves a more supportive business 
ecosystem (Garnsey & Leong, 2008), or identify one that they can enter.  The case study 
shows how MVP has drawn together stakeholders that have provided a supportive business 
ecosystem for SERUM (Moore, 1996).   
 
5. Conceptual framework: mobilizing resources to create value 
Public-private partnerships can create alternative avenues for incumbent firms to 
venture into new areas with a risk-mitigating and knowledgeable partner in order to achieve 
entrepreneurial-style innovations. An open innovation public-private partnership business 
model is a new alternative to the traditional in-house drug commercialization model of 
healthcare firms.  The open innovation business model allows each participant to contribute 
resources in accordance with their capabilities (Chesbrough, 2003). In any entrepreneurial 
undertaking whether in a new venture or in an established firm, resources are combined in 
new ways to create value for the activity (Garnsey, Dee, & Ford, 2006; Penrose, 1995).  By 
viewing entrepreneurial innovation in this light, we aim to extend entrepreneurship theory to 
the context of global health.  
The healthcare ecosystem is complex because of the many interdependent 
stakeholders involved.  To illustrate the role of the firm as a key player within the ecosystem, 
we draw on two streams of thought: entrepreneurial building of the resource-base (Figure 1) 
and the innovation value chain (Figure 2), which can provide a supportive ecosystem for an 
entrepreneurial firm (Figure 3).  Entrepreneurial value generation occurs in each of the firms 
that take part in the innovation value chain, as illustrated in Figure 3, so that the entire value 
chain becomes a value-adding innovation system.  
 
5.1 Applying the conceptual framework to case evidence  
5.1.1 Combining resources 
The firm’s business model represents the way the firm is organized to create and 
capture value (Garnsey, 2003; Teece, 2010).  This is depicted over the firm’s value 
generation cycle in Figure 1, showing the firm as an input-output system obtaining resources 
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from its ecosystem and transforming them into outputs of value to customers. The value 
generation process for given output requires a productive resource base that enables the 
entrepreneur to be an agent of change. Some innovating firms already have a resource base, 
while others have to build a resource base, and also access the resources of others in their 
ecosystem, before they can produce innovative output. Figure 1 depicts the resource base 
used to create output of value to users/customers, sometimes with the help of partners. The 
top loop shows efforts at building the resource base, which may be extensive for a new 
science-business in the life sciences. If the firm’s activity is to be sustained, it must capture 
some of the value created as returns over and above costs; returns may be distributed or 
reinvested to propel the next phase of the value generation cycle.  Because of the challenges 
they continually face, entrepreneurs often reconfigure their resources and search for 
opportunities using a different organizational base.  Resource constraints both limit and 
enable enterprise, restricting obvious options but encouraging new thinking outside 
conventions (Hugo & Garnsey, 2005).   
 
Figure 1: The value generation cycle. Adapted from Garnsey, et al., 2006 
An entrepreneurial firm is typically resource-constrained and creates competitive 
advantage not only from its own resource base, but rather from a unique assembly of 
resources (Penrose, 1995).  These may include critical resources from other organizations 
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that provide inputs (eg. investment) or help the firm produce its outputs on a complementary 
or collaborative basis.  In the case of global health enterprises, resources and knowledge that 
the firm does not immediately own may be accessible from resource providers through 
collaboration (Garnsey & Leong, 2008).  The study focuses on ways in which the 
entrepreneurial healthcare firm may be able to create a supportive ecosystem for itself 
through public-private partnerships.   
The theoretical underpinning of this approach comes from the resource-based theory 
(RBT) view of the firm, attributing differential firm performance to firms’ resource 
composition (Barney, 1991; Rumelt, Schendel, & Teece, 1991; Wernerfelt, 1984).  
Additional capabilities within the ecosystem can complement the firm’s resource base, while 
each value-creating firm helps contributes to the shared ecosystem through a process of 
mutual influence (Garnsey & Leong, 2008).  This is a way of operationalizing the notion that 
entrepreneurs actively utilize their networks to seek out the necessary knowledge and 
resources to form new combinations of intellectual and social capital (Nahapiet & Ghoshal, 
1998).   
Thus the value generation model depicts the way firms’ inputs (resources) can be 
organized and translated into outputs of increasing value – Figure 1 is a way of 
operationalizing the concept of the firm’s business model (Johnson, 2010; Teece, 2010).  
Every successful business model is structured to create value greater than its discrete inputs, 
and to engage customers prepared to pay for value and convert value to profits (Teece, 2010).  
The focal point in our depiction of value generation by the entrepreneurial firm is on the 
resource base that the firm builds and sustains, and how this is extended through 
collaborations with partners in its ecosystem.  It is by using its resources to deliver an 
offering that is affordable and meets user needs that the firm creates a value proposition for 
the customer (Johnson, 2010).  
Value generation can be seen as an emergent property of the firm as an input-output 
system. This model builds upon Penrose (1995) who argued that resource asynchronies are 
drivers of firm growth.  In a partnership model, internal firm resource asynchronies may be 
supplemented by partner sources in complementary combinations to drive new 
entrepreneurial activity for all participants.  
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5.2 Contributing to the innovation value chain and capturing value 
The innovation value chain involves the transformation of ideas into end products for 
the customer and requires the integration of idea discovery, idea development and idea 
diffusion (Afuah, 2003; Hansen & Birkinshaw, 2007).  This notion is built upon the 
manufacturing value chain concept of mapping out processes to transform raw materials into 
finished goods (Porter, 1980).  In a partnership business model, the innovation value chain 
becomes open to contributors who may specialize in one or more distinctive competencies.   
Where there is social as well as economic value to be created, each party may 
contribute to the mission to which other participants in the value chain are committed.  While 
most work on value creation has a focus on the creation and capture of economic value, 
increasingly it is realized that the social value created by enterprise and innovation is of no 
less importance.  Value captured by each stakeholder can be a combination of financial, 
technical and social value (Lepak, Smith, & Taylor, 2007).  Lepak’s (2007) review proposes 
two conditions for value creation: first, the monetary amount exchanged must exceed the 
producer’s costs of creating the value and second, the value enjoyed by the consumer must be 
perceived to be better than the consumer’s closest alternative.  The financial value captured 
by the firm is the difference between exchange value and production cost.  In addition,  
intangible value can be built, in the form of knowledge and skills, while social value created 
is created through the matching of innovation to an unmet consumer need that may result in 
positive externalities for society.  
This concept extends the notion of open innovation value (Chesbrough, 2003) to 
encompass social value; participants draw on internal and external knowledge and learning to 
create value while each partner is enabled to capture part of the overall increase in 
quantifiable economic value and unquantifiable but significant social value.  
Figure 2 below shows the innovation value chain as applied to healthcare.  This has a 
translation process from scientific discovery to use, with intermediary phases in clinical 
development to test efficacy and safety and delivery processes to reach patients in need 
(Commission on Intellectual Property Rights, 2006).  Value can be created and captured at 
each stage of the innovation value chain through a partnership model.  
     
  14 
 
Figure 2: The innovation value chain in healthcare. Adapted from (Commission on Intellectual Property Rights, 
2006; Hansen & Birkinshaw, 2007) 
Managers who recognize the importance of engaging with other stakeholders realize 
that there is a bi-directional relationship between the firm and other players in adjoining 
input-output constituencies (Donaldson & Preston, 1995). Unmet medical needs create a 
focused direction for innovation and involve primary stakeholders outside the direct chain of 
suppliers and customers.  
 
5.3 Innovation in the public-private partnership ecosystem  
To move from a conceptual scheme to specific instances, we can see for those 
developing remedies for neglected diseases in various parts of the innovation value chain, 
private public partnerships can offer resources and project management capability to integrate 
processes of collaboration.   
Figure 3 shows that entrepreneurial firms need not to be active in every stage of the 
innovation value chain of global heath, but can specialize within a innovation ecosystem 
towards a shared objective (Adner, 2006; Buse & Walt, 2000).  Value created by specialist 
firms at the discovery and development nodes of the innovation value chain can be 
transferred to delivery partners. This occurs where there is disintermediation (the reverse of 
vertical integration) among producer firms in the value chain.  The firms can draw on their 
resource base to create value for their customer, and also capture value in order to remain 
viable.  The firm’s customer may not be the final customer, but could be another intermediary 
participant in the overall innovation value chain.  Value creation along the innovation value 
chain, potentially involving more than one enterprise, can collectively generate value in a 
safe and efficacious therapeutic solution.  Central to the firm’s operations are its transaction 
partners, including suppliers, customers, co-innovators and resource providers.  Resource 
providers can provide support to several participants in the innovation ecosystem, together in 
pursuit of a common mission.  
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Figure 3: Value generating firms taking part in the innovation value chain of the global health innovation 
ecosystem 
In addition to the firm’s transaction partners, who can be thought of as primary 
stakeholders, the firm’s secondary stakeholders play an increasingly important role 
(Waddock, Bodwell, & Graves, 2002) in the business ecosystem but are often more difficult 
to identify (Hall & Martin, 2005).  Regulators, trusts and non-governmental organizations 
(NGOs) can directly impact firms’ activities and occupy both primary and secondary 
stakeholder positions.  Secondary stakeholders can also contribute to or disrupt competencies 
of the innovation value chain.  For example, the wider scientific community is affected by the 
commercialization of other health research, as discoveries and lessons are shared within the 
community generating positive externalities.  NGOs and advocacy groups take up causes and 
needs of the poor and raise awareness of commercially neglected issues.  
 
6. Public-private partnership ecosystem: the case of SERUM within the Meningitis 
Vaccine Project 
In what follows this conceptual framework is informed by evidence from a global 
public-private partnership, the Meningitis Vaccine Project (MVP) that produces 
MenAfriVacTM5, the world’s first meningococcal serotype A conjugate vaccine.  MVP is a                                                         
5 MenAfriVacTM received WHO prequalification and approval status on June 23, 2010 
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partnership coordinated by the United Nations World Health Organization (WHO) and 
Program for Appropriate Technology in Health (PATH). The vaccine obtained WHO 
approval on June 23, 2010 and launched its first mass vaccination campaign in Burkina Faso 
on December 6, 20106. 
The Need 
Meningococcal meningitis occurs when viruses or bacteria invade the protective 
membranes of the central nervous system and cause an adverse inflammatory response. 
Bacteria that penetrate the meninges have passed the crucial blood- brain barrier and can 
cause permanent damage to neural functions.  Even with aggressive treatment, case mortality 
is high, reaching up to 25% globally (Greenwood, 1999; Jodar, LaForce, Ceccarini, Aguado, 
& Granoff, 2003).  However, this may be underestimated due to the high number of cases in 
resource- poor settings where the patient does not reach the hospital-level for appropriate 
treatment and therefore no record is kept.  
In sub-Saharan Africa, N.meningitidis is of particular concern and is the bacteria with 
the greatest potential to cause epidemics in the semi-arid region stretching from Senegal 
(West Africa) to Ethiopia (East Africa) in what is known as the “African meningitis belt”.  
Meningitis bacteria are spread via sneezing and coughing and are perpetuated across African 
countries during the hot, windy season where cyclical epidemics affected up to 250,000 
people.  
Monitoring and evaluation of immunization schedules in developed countries have 
demonstrated efficacy as pharmaceutical companies responded to public health concerns 
(Trotter, Andrews, & Kaczmarski, 2004).  The meningococcal C conjugate vaccine was 
added to the UK immunization schedule in 1999 and Trotter’s study (2004) found a 
significant drop in meningococcal C disease after immunization and confirmed persistent 
vaccine effectiveness (90% at 4 years).  By contrast, no private manufacturer was willing to 
develop a meningococcal A conjugate vaccine, which is the serotype which predominately 
affects sub-Saharan Africa.  In 2000, a WHO report found that existing intellectual property 
on conjugation technology for a group A vaccine existed and if paired with international 
funding, a low-cost, high quality vaccine could be produced for Africa at a target price of 
US$0.40 per dose or less (LaForce, Konde, Viviani, & Preziosi, 2007).                                                                                                                                                                              
http://meningvax.com/ 
6 MVP Press releases - http://meningvax.com/ accessed December 16, 2010  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The Response: recognizing an opportunity and mobilizing resources 
Upon the 2000 issuance of the WHO recommendation, the Bill and Melinda Gates 
Foundation awarded a $70 million USD, 10-year grant to WHO and PATH to coordinate a 
global public-private partnership effort to eliminate meningococcal epidemics in the “African 
Meningitis Belt”.  
The MVP team chose the contract manufacturing approach to consolidate the 
intellectual property, technology and know-how to commercialize the vaccine.  In-depth 
discussions were held with WHO and African public health officials who emphasized that the 
commercial cost of the vaccine needed to be kept low to ensure wide patient access in 
endemic countries.  MVP signed up its first three commercialization partners in spring 2002 
(LaForce, et al., 2007).  SynCo Bio Partners, a Dutch biotechnology firm was to supply the 
meningococcal group A polysaccharide and the Centre for Biologics Evaluation and 
Research of the US Food and Drug Administration (CBER/FDA) was the lead on the 
technology transfer of conjugation technology.  The manufacturer position was chosen to be 
SERUM Institute of India, an emerging market supplier, prequalified and certified by WHO 
to make high quality vaccines. SERUM was founded in 1967 in Pune and is a member of the 
Poonawalla Group of Companies and fully owned by founder/owner Cyrus Poonawalla7. 
An Entrepreneurial Innovator: SERUM Institute  
SERUM’s competitive advantage in the vaccine business is in that it sells high quality 
vaccines at low cost.  Its central tenet is manufacturing capacity; economies of scale and low 
cost are top priorities (Mahalingam, 2008).  SERUM invests in additional infrastructure and 
capacity ahead of the market demand curve; thus its strategy is to be able to respond to surges 
in international demand ahead of its immediate competitors. SERUM continuously devotes 
R&D funding resources towards improving its product portfolio and the MVP project was a 
strategic fit for its new areas of research and collaboration8.  
SERUM had developed high quality, low cost vaccine products for over four decades.  
SERUM was able to attract and retain talented personnel to work on a wide range of vaccine 
products.  Cyrus Poonawalla and his long-serving staff at SERUM are well-known in the 
industry for their strong commitment to social values and interest in improving health                                                         
7 http://www.poonawallagroup.com/ - accessed January 10, 2010 
8 Discussion with MVP Lead, Dr. Marc La Force February 2010 and corroborated by R&D technical section on 
Serum website http://www.seruminstitute.com/ accessed February 2010  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outcomes. SERUM understood both the social need of the MVP project and the benefits of 
collaboration9. The WHO strategy for meningitis control prior to the commercialization of 
MenAfriVacTM was reactive mass vaccination with polysaccharide vaccines, but control was 
difficult due to timing and unreliable epidemiological surveillance (LaForce, Ravenscroft, 
Djingarey, & Viviani, 2009).  With the MenAfriVacTM proactive vaccination approach, there 
is greater chance of inducing herd immunity and saving more lives. 
MVP was organized on the basis of a division of labour in the innovation value chain.  
Basic discovery had been completed years prior through scientific efforts in commercializing 
other serotypes of meningococcal bacteria.  SERUM was chosen to do new product 
development for meningitis serotype A.  SERUM worked closely with co-developers SynCo 
who provided high-grade contract group A polysaccharide, and scientific partners in MVP 
from US, UK, Norway, Italy and Senegal.  Further clinical work was conducted in India, 
Kenya, the Gambia, Senegal and Ghana.  Development took place at SERUM headquarters, 
but a global effort was required to advance the vaccine through clinical trials and regulations.  
 
6.1 The entrepreneurial process and creating value through partnership 
Aggregating resources and capabilities to create value 
The Gates Foundation grant provided push funding for MVP to progress its work and 
MVP also benefitted from SERUM’s existing infrastructure. SERUM as a stand-alone 
organization prior to MVP collaboration already possessed a reputation for R&D innovation 
and high quality standards.  As a private enterprise with one sole owner, SERUM was able to 
streamline the decision-making process, allowing MVP to work immediately upon release of 
funding.10.  This proved attractive to external public partners and PATH, the chief product 
development coordinator.  
SERUM’s participation in the Meningitis Vaccine Project and its mode of innovation 
show a entrepreneurial matching of resources and opportunities, as described by Penrose 
(Penrose, 1960). SERUM adapted its internal resources to shift to a new area of vaccine 
development (meningitis A). The MVP product development partnership model allows for 
collaborative sharing of knowledge by stakeholders within the innovation value chain.  
Stakeholders can be private firms (such as SERUM) or public health delivery partners such                                                         
9 Discussion with MVP Lead, Dr. Marc LaForce February 2010  
10 Discussion with MVP Lead, Dr. Marc La Force February 2010 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as UNICEF and Medicines Sans Frontiere (Doctors without Borders)11.  The public-private 
partnership structure can be configured to act as a long-linked value chain in which core 
activities are split between contributors in idea discovery, development and diffusion.  
Partnership project management by PATH and WHO covers support functions of overall 
logistics (Porter, 1980; Stabell & Fjeldstad, 1998).  The firms within the ecosystem are 
differentiated by individual competencies (Barney, 1991), but they can create value for each 
other within the innovation value chain of the partnership when they share a common goal.  
SERUM is an established firm and shows ability to continuously renew its 
capabilities.  The founder is actively involved in daily operations and drives the 
entrepreneurial process of matching opportunities with available resources and prior 
knowledge.  The founder is able to combine social capital and intellectual capital through 
long-term commitments to their ventures and to their people (Garnsey & Heffernan, 2005).  
Firms are natural institutional settings conducive to the development of social capital that 
bind stakeholders of each project (Nahapiet & Ghoshal, 1998).  
The MVP partnership supports an ecosystem of public and private resources that has 
allowed for MenAfriVac’s commercialization.  SERUM has invested its own internal 
resources in building the manufacturing facility for the MenAfriVacTM vaccine.  SERUM 
reduces its development risk and financial risk by being part of MVP ecosystem.  MVP links 
together project management and provides SERUM access to discovery (upstream) and 
delivery (downstream) partners for the eventual product launch.  
Partnerships and external collaboration often result from the need to mitigate risk in 
the pioneering technical stages of product development (Eisenhardt & Schoonhoven, 1996). 
A unified medical and social mission binds together internal and external competencies of the 
firms within MVP.  SERUM draws upon the expertise from its MVP partners and suppliers 
as well as its coordinating partners PATH and WHO.  Establishing strategic alliances is a 
central function for many firms (Harrigan, 1988; Parkhe, 1993) to conserve resources and 
share risks (Hamel, Doz, & Prahalad, 1989).  Many advantages of risk sharing have been 
identified by global health funding and coordination bodies (Buse & Walt, 2000) to increase 
legitimacy for firms (Baum & Oliver, 1991) as allowing for opportunities to gain new 
competencies (Dyer & Singh, 1998; Hagedoorn, 1993).  MVP maintains the value network of                                                         
11 For full listing of Meningitis Vaccine Project partners please see http://meningvax.com/partners.php -- 
accessed November 1, 2010  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international alliances and processes of work distribution to leverage limited resources and 
knowledge.  
The partnership business model allows SERUM to overcome the long-term risk 
facing science-based business and to achieve the required knowledge integration and learning 
advocated by Pisano to make them viable (Pisano, 2010).  MVP is able to mitigate and 
reward long-term risk to ecosystem stakeholders through the resources pooled within the 
partnership.  It is also able to integrate across technical within a value chain to which 
stakeholders share information and share commitment to the mission.  Learning and 
knowledge are also achieved collectively among the MVP partners, because intellectual 
property and expertise are held by the partnership and not by any individual stakeholder.  All 
technical stakeholders are able to share lessons learned from failures and contribute technical 
resources to progress future iterations.  
 
Accessing resources in the MVP global health ecosystem  
 The resources of the MVP network open to SERUM provided technical advice, 
distribution advice and project management timeline guidance, further reducing risk and 
assisting knowledge integration.  The diagram below depicts the key resources assembled at 
SERUM for successful MenAfriVacTM development.  
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Figure 4: The value generation model applied to SERUM Institute of India (SIIL) Ltd 
 
The constructs of the value generation model in Figure 1 are informed by case 
evidence from MVP in Figure 4 above.  The resource base for SERUM combines both 
technical capabilities and market capabilities as a direct result of its central participation in 
the Meningitis Vaccine Project.  SERUM’s role in the innovation value chain was based on 
its competitive advantage and knowledge of product development.  Value creation for the 
customer solidified when pre-qualification was approved by WHO on June 23, 2010 
specifying that individual vaccines produced met international standards of quality, safety 
and efficacy12. Value has been captured by SERUM because the price on offer is above their 
costs and moreover they have gained on a learning curve as a result of knowledge transfer 
and technical expertise gained from the MVP ecosystem, especially the conjugation 
techniques from CBER/FDA.  This learning can be applied to future projects in SERUM’s                                                         
12 PATH press release June 23, 2010 http://www.path.org/news/an100623-menafrivac.php - accessed July 29, 
2010 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internal pipeline.  SERUM’s future value capture is ensured by margins expected from stable, 
long-term demand of MenAfriVacTM from international agencies.  The price for the first 25 
million doses of MenAfriVacTM is sold by SERUM at $0.396 USD, under original target 
profile mandate of < $0.40 USD (LaForce, et al., 2007).  There is also a governance process 
to monitor future price changes requiring price increases to be justified through a review 
process that includes PATH and WHO as coordinators of MVP.  For example, the per dose 
cost after the first 25 million doses will rise to $0.49 USD per dose based on increases of 
operational costs and raw materials13.  The technical knowledge achieved by SERUM as a 
further form of value capture from the MVP partnership is reinvested back into R&D product 
pipeline development and the financial value captured is reinvested in development of their 
manufacturing capacity.  
SERUM has harnessed existing prior intellectual property in vaccine conjugation 
techniques from the partnership.  SERUM’s key task was to tailor the vaccine to the 
meningitis A serotype and work with its clinical partners within MVP to demonstrate safety 
and efficacy.  Vaccine distribution and delivery is transferred to additional global partners 
such as NGOs and WHO working together with governments where the disease is endemic to 
conduct mass public health vaccination programs.  There is little global marketing and sales 
responsibility incumbent on SERUM.  MenAfriVacTM occupies a niche within the vaccine 
market and the MVP ecosystem ensures that the stakeholders in that market are coordinated 
and work collaboratively.   
                                                        
13 Per discussion with MVP Lead, Dr. Marc La Force March 2011  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Figure 5: SERUM occupies a development role in the innovation value chain for MVP, involving both primary 
and secondary stakeholders. 
Figure 5 illustrates SERUM operating at the development node of the innovation 
value chain.  Other organizations are operating along the value innovation chain to create 
complementary elements that contribute to the overall mission.  Figure 5 also shows that 
SERUM, as the entrepreneurial firm in the centre of the ecosystem, both affects and is 
affected by other stakeholders (Garnsey & Leong, 2008).  For example, SERUM strengthens 
its resource base with technology found in the discovery phase of the innovation value chain 
being used in the development phase.  In turn, SERUM’s commercialization work feeds into 
the resource base of MVP’s delivery partners.  Secondary stakeholders also affect the 
innovation value chain through external regulatory and policy control.  Public policy by 
countries affected in the African Meningitis Belt aim both to support R&D innovation of new 
vaccines (inputs), and to build the complementary assets such as underlying public delivery 
infrastructure (Teece, 1986).  In the case of the Meningitis Vaccine Project, no developing 
government directly contributed funds for the development partnership.  However, it was 
MVP coordinators, PATH and WHO, that contacted national governments during the 
development phase to enlist them to collaborate on vaccine roll-out strategies and open 
access for quick-country uptake upon approval14.  
                                                        
14 Per discussion with WHO Implementation Officer Dr. Carol Tevi-Benissan May 2010  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Using the ecosystem to generate and capture value 
Value creation based on SERUM’s resources and capabilities made it possible to 
provide an offering meeting customer needs (Lepak, et al., 2007).  The value generation 
model summary (Table 1) demonstrates how SERUM achieved value creation as specified by 
criteria set out by Lepak (2007).  SERUM achieved monetary returns greater production costs 
and the social value enjoyed by the consumer is above that of the closest available 
alternative.   
Table 1 below summarizes the constructs of the value generation model, applied to SERUM. 
SERUM Institute of India Ltd (SIIL) 
Year Founded 1967 
Health intervention Vaccines 
Resource base - Science and technology  
- People / founder 
Resource providers - Catalyst grant from 
Gates Foundation to 
establish MVP 
partnership 
- Internal resources 
Partners - MVP Team (21 primary 
stakeholders) 
Value creation 
(revenues generated) 
- Yes. Sales of 
meningococcal A 
conjugate vaccine 
MenAfriVacTM 
Value captured (profit) - In prospect through 
long-term contract with 
UNICEF 
- Intellectual property 
rights all housed within 
MVP with no imminent 
competitors 
- New knowledge 
transferred to SERUM  
Reinvestment in 
business idea  
- New vaccines in R&D 
pipeline 
- Manufacturing capacity 
 
The table illustrates the SERUM’s alignment of internal values and capabilities at 
SREUM with external incentives provided by MVP.  While Dr. Poonawalla, as the scientist 
entrepreneur, is interested in utilizing SERUM’s technology for alleviating social problems, 
to make the product development process viable, he has to mobilize additional resources 
from the supporting ecosystem.  
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SERUM’s integration into the public-private partnership ecosystem helps the firm 
create and capture value.  The Meningitis Vaccine Project tied 21 primary stakeholders 
together in pursuit of a common purpose and allowed SERUM to match its capabilities with 
the opportunities offered by the partnership ecosystem.  SERUM’s technical risk was reduced 
by involvement of development partners including US Food and Drug Administration and 
Dutch polysaccharide developer, SynCo Bio Partners in MVP and weekly and monthly 
review meetings with MVP coordinators at WHO and PATH.  Leveraging existing 
technology brought into the partnership by other partners and funding from the Gates 
Foundation grant lowered financial investment requirements for SERUM.  Delivery and 
distribution partners in MVP also ensured SERUM did not have to build a sales and 
marketing force.  Along with financial and intellectual property value garnered from MVP, 
the social value captured by the firm involves utilization of the vaccine in the sub-Saharan 
African Meningitis Belt, reducing meningitis fatalities. The public health goal is to vaccinate 
300 million people living in the African meningitis belt by 2015 and thereby ridding the 
region of meningitis A15.  SERUM has also been able to achieve a positive international 
media image through its participation in the MVP partnership and further enhance its profile 
as a quality vaccine manufacturer.  
SERUM actively contributed back to the MVP ecosystem.  SERUM’s participation 
allowed MVP coordinators to negotiate a cost-plus price for the final product and reach a 
target product profile of a vaccine with a specified low-price.  This had not proved achievable 
in 2002 in negotiations with other fully-integrated vaccine manufacturers.  SERUM 
contributed manufacturing expertise and made its own investment into upgrading capacity for 
final vaccine production, which allowed ecosystem delivery partners to concentrate on 
distribution.   
SERUM is able to reinvest back into its operations monetary, technical and social 
value sourced from its adapted business model.  The literature suggests that firms are more 
likely to innovate and match resources with opportunities in new ways when they face 
uncertain environments and are managed by entrepreneurial managers (Brown & Eisenhardt, 
1997; Smith, Collins, & Clark, 2005).  Although SERUM has long-standing operations in the 
vaccine industry, technological innovation in new scientific areas is a still high-risk 
proposition.  The owner and founder, Dr. Poonawalla, has extensive social networks and                                                         
15 Mission statement per MVP Project http://meningvax.org/  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builds on a track record of innovation.  However the creation of new knowledge through 
interactions and sharing of knowledge both internally and externally with partners has been 
further stimulus and support to entrepreneurial innovation, as it could be elsewhere (Nahapiet 
& Ghoshal, 1998). 
 
7. Implications and conclusions 
A conceptual framework setting value generation by the innovator firm in the context 
of its ecosystem allows issues of entrepreneurship, innovation and ecosystem stakeholders to 
be examined on a coherent basis.  The conceptual lenses of value generation and the business 
ecosystem provided us with focus on what was initially very involved and unclear evidence.  
Our evidence showed how a enterprise-based solution was reached for vaccine development 
by a company that drew on an innovative ecosystem in assembling the resources required. 
This provides some generic lessons from a specific instance.   
The evidence illustrates how resources and capabilities can be developed by an 
enterprising healthcare business, even in the face of considerable constraints, through 
integration of resources within a supportive ecosystem (Conner & Prahalad, 1996; Grant, 
1991). The public-private product development partnership model coordinates the activities 
of the individual firm within the innovation value chain and allows each stakeholder to both 
create and harness value. However this required initiative and vision from the various parties 
involved. Whether the partnership model is an effective catalyst of entrepreneurial activity in 
all other disease areas is an avenue for future research. 
Resource-based theory is often applied to innovative firms in resource-rich 
environments and infrequently mentioned in development or bottom of pyramid research 
literature. In examining the value generation cycle for SERUM within the public-private 
partnership model, we have addressed two specific aspects of the resource-based perspective 
of the firm and extended conventional entrepreneurship theory to global health.  The value 
generation model made it possible to map the development of distinctive resources by 
SERUM (Garnsey, et al., 2006).  SERUM has become the global supplier of the Meningitis A 
vaccine by assembling a unique set of resources and capabilities (Penrose, 1995) within a 
configuration of partnerships  - a form of open innovation.  SERUM has extended its original 
R&D activities and internal competencies in vaccine production to address a new disease 
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area.  The participation within the MVP partnership has encouraged entrepreneurial activity 
in extending firm capabilities (MacDonald, 1985).  
The logic of inquiry is to examine the positioning of the main unit of analysis within 
the innovation value chain and in relation to other units of the global health ecosystem.  
SERUM is not threatened by its participation in open innovation because it built unique 
resources which operate as entry barriers because they are hard-to-imitate and non-
substitutable (Barney, 1991) and thus a  basis for sustaining value generation.  Under the 
direction of the entrepreneurial founder-manager, SERUM provided an offering of value to 
users and the ecosystem (Bowman & Ambrosini, 2000; Lepak, et al., 2007).  Entrepreneurial 
activity has taken place within a business ecosystem that was itself enacted by the impetus of 
innovative participants (Rumelt, 1997).  
Economic incentives for commercial firms in the area of global health have long been 
unfavourable (Buse & Waxman, 2001).  However, risk-mitigating R&D funding can improve 
incentives for entrepreneurs (Karamchandani, et al., 2009; Ravishankar, et al., 2009) resulting 
in increased investments (London, 2009).  Government and donor policy have greatly 
increased push and pull mechanisms encouraging new ideas, initiatives and alliances.  The 
healthcare value chain can be supported by public grants that decrease the entry risk barriers 
for entrepreneurial firms.  In a field where private-sector entrepreneurship had previously 
been lacking, the SERUM case illustrates the founder/entrepreneur’s ability to draw on 
personal and extended networks (Dubini & Aldrich, 1991) to keep human capital motivated 
and establish legitimacy (Aldrich & Fio, 1994).  The MVP program has created an innovation 
ecosystem by uniting primary and secondary stakeholders in global health.  The ecosystem is 
able to pull together resources enabling the innovation value chain to draw on multiple 
resources to develop an effective vaccine.   
There is growing recognition that entrepreneurial healthcare firms can make 
contributions to the global health ecosystem and respond to growth opportunities at the 
bottom of the pyramid.  We have outlined the global need to fight health inequities, pointed 
to changes in global incentives and illustrated a commercialization business model based on 
catalyzing the ecosystem as a whole.  How will future innovators and entrepreneurs respond 
to the grand challenge of global health? What kinds of new business models will emerge to 
provide affordable healthcare for the poor? What financing mechanisms can support the 
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reconciliation of innovation and access along the innovation value chain? These questions 
underlie the importance of research on entrepreneurship and global health.  
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